OpGen

OpGen Net Debt/Equity

The Net Debt to Equity Ratio of OpGen (OPGN) as of Nov 2, 2026 is 0.04. In the previous year, Net Debt to Equity Ratio was -1.03 — a change of -104.02% (higher).

Net Debt/Equity

0.04

YoY

-104.02%

Last updated:

Net Debt to Equity Ratio of OpGen is 2025 0.04 . Net Debt to Equity Ratio of OpGen was 2024 -1.03 . It decreases by -104.02% higher compared to the previous year.

The OpGen Net Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/Equity
Date
Net Debt/Equity
Jan 1, 2017
-0.39 USD
Jan 1, 2018
-0.81 USD
Jan 1, 2019
0.48 USD
Jan 1, 2020
0.45 USD
Jan 1, 2021
-0.26 USD
Jan 1, 2022
0.98 USD
Jan 1, 2023
-1.03 USD
Jan 1, 2025
0.04 USD
The OpGen Net Debt/Equity history
YEARNet Debt/EquityYoY
0.04-104.02%
-1.03-205.32%
0.98-469.27%
-0.26-159.07%
0.45-6.15%
0.48-158.96%
-0.81+105.64%
-0.39-54.89%
-0.87+5.64%
-0.83+167.41%
-0.31—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OpGen Stock analysis

What does OpGen do? OpGen, Inc. generates revenue through its Acuitas-branded high-resolution DNA tests and bioinformatics solutions, targeting healthcare providers and hospitals globally. The company's molecular diagnostics and informatics products help combat infectious diseases by providing precise diagnostic information on life-threatening infections and multidrug-resistant microorganisms. These solutions guide clinicians in managing patient outcomes and hospital biome protection through customized screening and surveillance. The firm's DNA tests and bioinformatics address antibiotic resistance, offering data-driven insights for healthcare decision-making. The company's Acuitas trade name is used for its high-resolution DNA tests, which are marketed to healthcare settings focused on infectious disease management. OpGen's products help hospitals manage patient care decisions and protect against the spread of infections caused by multidrug-resistant pathogens. The firm's global network of customers and partners includes healthcare providers seeking to implement pathogen surveillance systems for improved infection control. OpGen's business model centers on delivering molecular information solutions that combine DNA testing with bioinformatics, creating a comprehensive approach to infectious disease management. The company's focus on antibiotic resistance and multidrug-resistant microorganisms drives demand for its Acuitas products, which are positioned as tools for guiding clinical decisions and optimizing hospital infection control protocols. OpGen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OpGen stock

Net Debt to Equity Ratio of OpGen is 0.04 in 2025.

Net Debt to Equity Ratio of OpGen changed from -1.03 to 0.04, representing a -104.02% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Equity Ratio OpGen since 2006 – with annual values, charts, and detailed analysis.

Net Debt/Equity adjusts the debt-to-equity ratio by subtracting cash from total debt. It provides a more accurate picture of actual leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Equity Ratio's OpGen with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — OpGen

All Key Metrics — OpGen